Prosecution Insights
Last updated: April 19, 2026

AstraZeneca AB

31 pending office actions

Portfolio Summary

31
Total Pending OAs
7
Final Rejections
24
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
19045166 STABLE, AQUEOUS FORMULATIONS OF ANTIBODIES THAT BIND IL5 RECEPTOR KIM, YUNSOO 1641 Final Rejection Feb 04, 2025
18855182 PREDICTING ALBUMINURIA USING MACHINE LEARNING HEIN, DEVIN C 3686 Non-Final OA Oct 08, 2024
18443829 SPIROCYCLIC COMPOUNDS HABTE, KAHSAY 1624 Non-Final OA Feb 16, 2024
18421142 COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS STAVROU, CONSTANTINA E 1632 Non-Final OA Jan 24, 2024
18564778 METHODS OF TREATING BREAST CANCER FETTEROLF, BRANDON J 1626 Non-Final OA Nov 28, 2023
18492216 METHODS OF TREATMENT OF BREAST CANCER SCHMIDT, IZABELA MARIA 1621 Non-Final OA Oct 23, 2023
18552014 FORMULATION COMPRISING CERALASERTIB LEE, SIN J 1613 Final Rejection Sep 22, 2023
18470548 PCSK9 INHIBITORS AND METHODS OF USE THEREOF JACKSON, SHAWQUIA 1626 Non-Final OA Sep 20, 2023
18550548 CONTROL OF MULTI-GENE EXPRESSION USING SYNTHETIC PROMOTERS SMITH, ADAM MICHAEL 1638 Non-Final OA Sep 14, 2023
18550546 SYSTEM AND METHOD FOR ONLINE DETECTION OF A POST-TRANSLATIONAL MODIFICATION OF A POLYPEPTIDE BERKE-SCHLESSEL, DAVID W 1651 Non-Final OA Sep 14, 2023
18452008 PHARMACEUTICAL PROCESS AND INTERMEDIATES OH, TAYLOR V 1625 Non-Final OA Aug 18, 2023
18448559 COMBINATION THERAPIES FOR TREATMENT OF CIRRHOSIS WITH PORTAL HYPERTENSION REDWOOD, CHRISTOPHER EVAN 1629 Non-Final OA Aug 11, 2023
18264526 NEW METHOD TO PRONOSTIC LUNG CANCER VOLKOV, ALEXANDER ALEXANDROVIC 1677 Non-Final OA Aug 07, 2023
18262934 CLINICAL ENDPOINT ADJUDICATION SYSTEM AND METHOD PATEL, SHERYL GOPAL 3685 Final Rejection Jul 26, 2023
18337476 N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)QUINOLINE-4-CARBOXAMIDES MCDOWELL, BRIAN E 1624 Non-Final OA Jun 20, 2023
18257123 N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES ANDERSON, REBECCA L 1626 Final Rejection Jun 13, 2023
18253280 STEROID SPARING HADDAD, MAHER M 1641 Non-Final OA May 17, 2023
18248280 TREATMENT OF FLARES IN LUPUS XIE, XIAOZHEN 1674 Non-Final OA Apr 07, 2023
18247014 COMPOUNDS AND THEIR USE IN TREATING CANCER TOWNSLEY, SARA ELIZABETH 1629 Non-Final OA Mar 28, 2023
18171735 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer AULAKH, CHARANJIT 1621 Non-Final OA Feb 21, 2023
17926235 TUMOR MUTATIONAL BURDEN ASSOCIATED WITH SENSITIVITY TO IMMUNOTHERAPY IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA AEDER, SEAN E 1642 Non-Final OA Nov 18, 2022
18056367 LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS PYLA, EVELYN Y 1633 Non-Final OA Nov 17, 2022
17998275 ATR INHIBITORS FOR THE TREATMENT OF CANCER HIRAKIS, SOPHIA P 1623 Non-Final OA Nov 09, 2022
18046173 COMBINATION REDDIG, PETER J 1646 Final Rejection Oct 13, 2022
17917333 COMPOSITIONS AND METHODS FOR IMPROVED SITE-SPECIFIC MODIFICATION ALLEN, SARAH ELIZABETH 1637 Non-Final OA Oct 06, 2022
17755801 TYPE I INTERFERON INHIBITION IN SYSTEMIC LUPUS ERYTHEMATOSUS KIM, YUNSOO 1641 Final Rejection May 09, 2022
17772187 DRY POWDER FORMULATIONS CONTAINING LEUCINE AND TRILEUCINE HAGHIGHATIAN, MINA 1616 Non-Final OA Apr 27, 2022
17765585 METHODS AND COMBINATIONS FOR THE TREATMENT OF CANCER USING IMMUNE CHECKPOINT INHIBITOR ANTIBODIES CHATTIN, AMY MARIE 1643 Non-Final OA Mar 31, 2022
17754258 COMBINATION TREATMENT FOR CANCER DARPOLOR, JOSEPHINE KEBBEH 1642 Non-Final OA Mar 29, 2022
17529574 Compositions and Methods for Treating Late Stage Lung Cancer HECK, BRYAN WILLIAM 1643 Non-Final OA Nov 18, 2021
17318017 METHODS AND COMBINATIONS FOR THE TREATMENT OF CANCER USING IMMUNE CHECKPOINT INHIBITOR ANTIBODIES BUTTICE, AUDREY L 1647 Final Rejection May 12, 2021

Managing AstraZeneca AB's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month